While its role in diabetes is well established, semaglutides impact on weight loss has gained significant attention
A post-hoc analysis of SURMOUNT-5 estimated a larger reduction in predicted 10-year cardiovascular risk with tirzepatide (23.7%) than semaglutide (13.6%), but these are modeled projections, not measured outcomes
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress
Avoid repeated freezing and thawing
It's crucial for Psychiatry to start using these medications to minimize cardiometabolic, renal and cognitive risks, besides addiction risk